NCT05567601View on ClinicalTrials.gov

Doxil/Caelyx BE Study

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 16, 2023

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions
Ovarian CancerAIDS-related Kaposi SarcomaMultiple MyelomaMetastatic Breast Cancer
Interventions
DRUG

DOXIL/CAELYX

40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein

Trial Locations (14)

221005

Swami Har Shankaranand, Varanasi

391760

Kailash Cancer Hospital and Research Centre, Goraj

395017

Unique Hospital Multispeciality & Research Institute, Surat

412105

Indrayani Hospital, Pune

416234

Kolhapur Cancer Center, Kolhāpur

422002

HCG Manavata Cancer Centre, Nashik

444605

Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, Amravati

492001

Sanjeevani CBCC USA Cancer Hospital, Raipur

520002

HCG City Cancer Centre, Vijayawada

530040

Omega Hospital, Visakhapatnam

560072

Oncoville Cancer Hospital & Research Centre, Bengaluru

560092

Medstar Speciality, Bangalore

638012

Erode Cancer Centre, Erode

751007

Sparsh Hospital & Critical Care Ltd., Bhubaneshwar

All Listed Sponsors
lead

Baxter Healthcare Corporation

INDUSTRY

NCT05567601 - Doxil/Caelyx BE Study | Biotech Hunter | Biotech Hunter